Related Experiment Videos
Acquired perforating dermatosis in a British dialysis population
C A Morton1, I S Henderson, M C Jones
1Department of Dermatology, Ninewells Hospital, Dundee, U.K.
The British Journal of Dermatology
|November 1, 1996
Summary
Acquired perforating dermatosis (APD) affects 11% of British dialysis patients, often linked with diabetes. Treatments like steroids and retinoids showed effectiveness in managing this skin condition.
Area of Science:
- Dermatology
- Nephrology
Background:
- Acquired perforating dermatosis (APD) is a skin disorder linked to chronic renal failure and diabetes.
- It affects up to 10% of North American dialysis patients, but its prevalence in the UK was unknown.
Purpose of the Study:
- To determine the prevalence and clinical presentation of APD in a British dialysis population.
- To assess disease management and outcomes in these patients.
Main Methods:
- A skin survey was conducted on 80 dialysis patients.
- 72 patients participated, with APD diagnosis confirmed via clinical presentation and histology.
Main Results:
- The prevalence of APD was found to be 11% in the surveyed British dialysis population.
- Seven of the eight APD patients also had diabetes. Lesions typically presented as pruritic papules with central crusts.
- Topical/intradermal steroids or topical retinoids were effective therapies, with clinical clearance achieved in 5/7 treated patients within 3-12 months.
Conclusions:
- APD is as prevalent in British dialysis patients as in North America.
- A strong association between APD and long-standing diabetes in patients with chronic renal failure was confirmed.